AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1009-1017

  Liu, Gang ^a   Sprenger, Cynthia ^a,b   Sun, Shihua ^a   Epilepsia, Kathryn Soriano ^a   Haugk, Kathleen ^b   Zhang, Xiaotun ^a   Coleman, Ilsa ^c   Nelson, Peter S ^c   Plymate, Stephen ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Veterans Puget Sound Health Care System   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; KI 67 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN VARIANT; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTOME; UVOMORULIN; VIMENTIN; WNT11 PROTEIN; ANDROGEN BINDING PROTEIN; FOXA1 PROTEIN, MOUSE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; ISOPROTEIN; PROBASIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CASTRATION; CONTROLLED STUDY; DISEASE COURSE; DNA FRAGMENTATION; EPITHELIUM HYPERPLASIA; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE WEIGHT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR GROWTH; ANIMAL; CASTRATION RESISTANT PROSTATE CANCER; CELL TRANSFORMATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; MALE; METABOLISM; METASTASIS; ORCHIECTOMY; PROMOTER REGION;

ANDROGEN-BINDING PROTEIN; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; ORCHIECTOMY; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84884377857     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13784     Document Type: Article

References (38)

1. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, and Jenster G (2010). Bypass mechanisms of the androgen receptor pathway in therapyresistant prostate cancer cell models. PloS One 5, e13500.
2. Harris WP, Mostaghel EA, Nelson PS, and Montgomery B (2009). Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6, 76-85.
3. Attar RM, Takimoto CH, and Gottardis MM (2009). Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 15, 3251-3255.
4. Attard G, Sarker D, Reid A, Molife R, Parker C, and de Bono JS (2006). Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 95, 767-774.
5. Ang JE, Olmos D, and de Bono JS (2009). CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castrationresistant prostate cancer. Br J Cancer 100, 671-675.
6. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, and Nelson PS (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68, 4447-4454.
7. Taplin ME and Balk SP (2004). Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91, 483-490.
8. Kaur R, Yuan X, Lu ML, and Balk SP (2008). Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate 68, 1510-1516.
9. Yuan X and Balk SP (2009). Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27, 36-41.
10. Heinlein CA and Chang C (2002). Androgen receptor (AR) coregulators: an overview. Endocr Rev 23, 175-200.
11. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, and French FS (2004). The androgen axis in recurrent prostate cancer. Clin Cancer Res 10, 440-448.
12. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar Lopez F, Vessella RL, and Plymate SR (2011). Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PloS One 6, e27970.
13. Shafi AA, Cox MB, and Weigel NL (2013). Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78, 548-554.
14. Dehm SM and Tindall DJ (2011). Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18, R183-R196.
15. Guo Z and Qiu Y (2011). A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci 7, 815-822.
16. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, and Tindall DJ (2008). Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68, 5469-5477.
17. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, et al. (2009). A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69, 2305-2313.
18. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. (2009). Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69, 16-22.
19. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, Duclos B, Bergerat JP, Ceraline J, and Kurtz JE (2010). Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 31, 74-80.
20. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et al. (2010). Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120, 2715-2730.
21. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, and Sawyers CL (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107, 16759-16765.
22. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, and Wikstrom P (2011). Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PloS One 6, e19059.
23. Hu R, Isaacs WB, and Luo J (2011). A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71, 1656-1667.
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92, 3439-3443.
25. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, et al. (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64, 2270-2305.
26. Zeisberg M and Neilson EG (2009). Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119, 1429-1437.
27. Thiery JP, Acloque H, Huang RY, and Nieto MA (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
28. Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454.
29. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, et al. (2012). Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72, 3457-3462.
30. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256.
31. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406.
32. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, and Wu H (2012). Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72, 1878-1889.
33. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834.
34. Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, et al. (2012). Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. JExp Med 209, 697-711.
35. Hirsch HA, Iliopoulos D, and Struhl K (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 110, 972-977.
36. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, and Nelson PS (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18, 1359-1368.
37. [Francis JC, Thomsen MK, Taketo MM, and Swain A (2013). β-Catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet 9, e1003180.
38. Chen G, Goto Y, Sakamoto R, Tanaka K, Matsubara E, Nakamura M, Zheng H, Lu J, Takayanagi R, and Nomura M (2011). GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor. Biochem Biophys Res Commun 404, 809-815.